Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Leber hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial disease whose primary clinical manifestation is bilateral visual loss. Only a single therapy, idebenone, is approved in Europe for use in exceptional circumstances and no therapy is currently approved in the USA. LHON remains a disease with a high unmet medical need. This is a report of an open-label, single-center, dose-escalation study that evaluated the safety and tolerability of lenadogene nolparvovec in 15 subjects with LHON for up to 5 years following a single intravitreal injection at four dose levels. Subjects were enrolled sequentially in four cohorts followed by an additional cohort at the dose selected, and safety was assessed by an independent data safety monitoring board (DSMB) prior to any dose escalation. Overall, the treatment was well tolerated during the 5-year follow-up. No serious adverse events were considered related to treatment, no unexpected adverse events occurred, and no grade 3 or 4 Common Terminology Criteria for Adverse Events were reported. Anterior chamber inflammation and vitritis were mostly managed with topical steroids, and ocular inflammation was considered to be dose limiting by the DSMB based on the benefits/risks for the subjects. Analysis of the logarithm of the minimal angle of resolution (LogMAR) visual acuity in both treated and untreated eyes showed clinically relevant and durable improvements compared with baseline. Mean improvements of − 0.44 and − 0.49 LogMAR for treated and untreated eyes, respectively, were noted, with a mean (± standard deviation) final value of LogMAR + 1.96 ± 0.60 and + 1.65 ± 0.34, respectively, at 5 years post-treatment administration. For the six subjects treated with the optimal dose level (9 × 10 10 viral genomes [vg]/eye), the mean visual acuity improvement from baseline reached − 0.68 LogMAR for treated eyes and − 0.64 LogMAR for untreated eyes, with a mean final value of LogMAR + 1.77 ± 0.52 and + 1.78 ± 0.34, respectively. While there was a meaningful improvement in visual acuity for REVEAL subjects, the final visual acuity was less favorable than that seen in the two subsequent pivotal phase III studies in which subjects were treated earlier during the course of their disease. Lenadogene nolparvovec was well tolerated with a good safety profile during 5 years of follow-up and may offer meaningful lasting improvements in vision for this LHON population. EUDRACT N° 2013-001405-90.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The dose of lenadogene nolparvovec selected in REFLECT (9 × 1010 vg/eye) was the maximal tolerated dose determined in the previous phase 1/2a REVEAL study.15,21”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“It is also the first clinical study assessing the efficacy of a bilateral IVT of lenadogene nolparvovec, while in the three previous clinical studies REVEAL,21 REVERSE16–18 and RESCUE,17–19 lenadogene nolparvovec was exclusively administered as unilateral IVT.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy
Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., & Nikoskelainen, E. K. (1988) · Science · doi:10.1126/science.3201231 · Cited by 2,440 · cited 2×
“LHON was the first inherited human disease associated with point mutations in the mitochondrial DNA (mtDNA) [2] and is considered the most common inherited genetic mitochondrial disorder [3].”
BackgroundISCEV Standard for full-field clinical electroretinography (2015 update)
McCulloch, D. L., Marmor, M. F., Brigell, M. G., Hamilton, R., Holder, G. E., Tzekov, R., & Bach, M. (2015) · Documenta Ophthalmologica · doi:10.1007/s10633-014-9473-7 · Cited by 1,313
ISCEV Standard for full-field clinical electroretinography (2008 update)
Marmor, M. F., Fulton, A. B., Holder, G. E., Miyake, Y., Brigell, M., Bach, M., & (for the International Society for Clinical Electrophysiology of Vision) (2009) · Documenta Ophthalmologica · doi:10.1007/s10633-008-9155-4 · Cited by 1,003
Zingg, B., Chou, X.-L., Zhang, Z.-G., Mesik, L., Liang, F., Tao, H. W., & Zhang, L. I. (2017) · Neuron · doi:10.1016/j.neuron.2016.11.045 · Cited by 752
Standardizatlon of Vitreal inflammatory Activity in Intermediate and Posterior Uveitis
Nussenblatt, R. B., Palestine, A. G., Chan, C.-C., & Roberge, F. (1985) · Ophthalmology · doi:10.1016/s0161-6420(85)34001-0 · Cited by 684 · cited 1×
“Anterior chamber inflammation and vitritis were mostly assessed as mild in severity, with anterior chamber cell grade of 1 + or lower (according to Standardization of Uveitis Nomenclature Working Group criteria; scores range from 0 to 4 + , with lower scores indicating less cells visible in the anterior chamber and lo…”
BackgroundA randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., et al. (2011) · Brain · doi:10.1093/brain/awr170 · Cited by 578 · cited 3×
“Therapeutic options for adolescent and adult patients with LHON are currently limited to idebenone, and its benefits in patients with ND4 LHON are limited [19, 20].”
BackgroundInfluentialLeber hereditary optic neuropathy
Man, P. Y. W., Turnbull, D. M., & Chinnery, P. F. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.3.162 · Cited by 520 · cited 1×
“It is estimated that approximately 50% of males and 10% of females who carry one of the primary point mutations will manifest the clinical disease [6].”
BackgroundRiordan-Eva, P., Sanders, M. D., Govan, G. G., Sweeney, M. G., Costa, J. D., & Harding, A. E. (1995) · Brain · doi:10.1093/brain/118.2.319 · Cited by 490
The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Man, P. Y. W., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 483 · cited 1×
“LHON was the first inherited human disease associated with point mutations in the mitochondrial DNA (mtDNA) [2] and is considered the most common inherited genetic mitochondrial disorder [3].”
BackgroundInherited mitochondrial optic neuropathies
Yu-Wai-Man, P., Griffiths, P. G., Hudson, G., & Chinnery, P. F. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2007.054270 · Cited by 430 · cited 1×
“Classically, subjects become affected between the age of 15 and 35 years, but onset of LHON has been reported at almost any age, from 2 to 87 years, in both men and women [14, 16, 17].”
BackgroundNewman, N. J., Lott, M. T., & Wallace, D. C. (1991) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)76784-4 · Cited by 403 · cited 5×
“LHON is a rare disease, with an estimated prevalence of between 1 in 30,000 and 1 in 50,000 reported in Northern Europe [4, 12, 13].”
BackgroundInfluentialYu-Wai-Man, P., Newman, N. J., Carelli, V., Moster, M. L., Biousse, V., Sadun, A. A., Klopstock, T., Vignal-Clermont, C., Sergott, R. C., Rudolph, G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz7423 · Cited by 232 · cited 13×
“Among these subjects, one death was related to one SAE (septic shock secondary to endocarditis), which was assessed as unrelated to the study drug or the IVI procedure.”
BackgroundInfluentialSelf-citationGene Therapy for Leber Hereditary Optic Neuropathy
Feuer, W. J., Schiffman, J. C., Davis, J. L., Porciatti, V., Gonzalez, P., Koilkonda, R. D., Yuan, H., Lalwani, A., Lam, B. L., & Guy, J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.025 · Cited by 230
Carelli, V., Carbonelli, M., de Coo, I. F., Kawasaki, A., Klopstock, T., Lagrèze, W. A., La Morgia, C., Newman, N. J., Orssaud, C., Pott, J. W. R., et al. (2017) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000570 · Cited by 228
Self-citationEpidemiology and penetrance of Leber hereditary optic neuropathy in Finland
Puomila, A., Hämäläinen, P., Kivioja, S., Savontaus, M.-L., Koivumäki, S., Huoponen, K., & Nikoskelainen, E. (2007) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201828 · Cited by 213 · cited 1×
“LHON is a rare disease, with an estimated prevalence of between 1 in 30,000 and 1 in 50,000 reported in Northern Europe [4, 12, 13].”
BackgroundNewman, N. J., & Biousse, V (2004) · Eye · doi:10.1038/sj.eye.6701591 · Cited by 210
Hereditary optic neuropathies: from the mitochondria to the optic nerve.
Newman, N. J. (2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.017 · Cited by 209 · cited 2×
“22 per 100,000 people, and it is estimated that 2% of Australians aged < 65 years who are registered as legally blind have visual loss from LHON [14].”
BackgroundGene Therapy for Leber Hereditary Optic Neuropathy
Guy, J., Feuer, W. J., Davis, J. L., Porciatti, V., Gonzalez, P. J., Koilkonda, R. D., Yuan, H., Hauswirth, W. W., & Lam, B. L. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.016 · Cited by 204 · cited 3×
“There is currently no approved treatment for LHON in the USA.”
BackgroundInfluentialNikoskelainen, E. K., Huoponen, K., Juvonen, V., Lamminen, T., Nummelin, K., & Savontaus, M.-L. (1996) · Ophthalmology · doi:10.1016/s0161-6420(96)30665-9 · Cited by 200 · cited 2×
“Visual loss typically progresses to a nadir over a median of 6–8 weeks [9], and one study reported that 94% of subjects with available data reached nadir within 8 weeks of the onset of visual loss [10].”
BackgroundLeber’s Hereditary Optic Neuropathy
Sadun, A. A., Morgia, C. L., & Carelli, V. (2011) · Current Treatment Options in Neurology · doi:10.1007/s11940-010-0100-y · Cited by 190
A neurodegenerative perspective on mitochondrial optic neuropathies
Yu-Wai-Man, P., Votruba, M., Burté, F., La Morgia, C., Barboni, P., & Carelli, V. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1625-2 · Cited by 176 · cited 4×
“The 11778-ND4 mutation is the most frequent, accounting for about 75% of LHON in North America and Europe [1, 4, 7].”
BackgroundInfluentialNewman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Biousse, V., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Barboni, P., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.12.012 · Cited by 168
Self-citationEK, N., K, H., V, J., T, L., K, N., & ML., S. (1997) · Journal of Neuro-Ophthalmology · doi:10.1097/00041327-199703000-00027 · Cited by 158
Leber’s Hereditary Optic Neuropathy with Childhood Onset
Barboni, P., Savini, G., Valentino, M. L., La Morgia, C., Bellusci, C., De Negri, A. M., Sadun, F., Carta, A., Carbonelli, M., Sadun, A. A., et al. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0520 · Cited by 146
Redistribution of metabolic resources through astrocyte networks mitigates neurodegenerative stress
Cooper, M., Pasini, S., Lambert, W. S., D’Alessandro, K. B., Yao, V., Risner, M. L., & Calkins, D. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009425117 · Cited by 141 · cited 1×
“Transfer of mitochondrial material (messenger RNA, proteins) cannot be excluded as a possible contributing mechanism of the visual improvement in the non-treated eye [32].”
BackgroundLong-term outcomes of gene therapy for the treatment of Leber’s hereditary optic neuropathy
Yang, S., Ma, S.-Q., Wan, X., He, H., Pei, H., Zhao, M.-J., Chen, C., Wang, D.-W., Dong, X.-Y., Yuan, J.-J., et al. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.07.002 · Cited by 139
Leber's hereditary optic neuropathy: correlations between mitochondrial genotype and visual outcome.
Oostra, R. J., Bolhuis, P. A., Wijburg, F. A., Zorn-Ende, G., & Bleeker-Wagemakers, E. M. (1994) · Journal of Medical Genetics · doi:10.1136/jmg.31.4.280 · Cited by 121 · cited 1×
“[26] reported a mean final visual acuity of 20/182 in the better seeing eyes of patients with the 11778-ND4 mutation in another retrospective study, with only 19% of these eyes having a final visual acuity better than 20/200.”
BackgroundQuality of Life in Patients with Leber Hereditary Optic Neuropathy
Kirkman, M. A., Korsten, A., Leonhardt, M., Dimitriadis, K., de Coo, I. F. M., Klopstock, T., Griffiths, P. G., Hudson, G., Chinnery, P. F., & Yu‐Wai‐Man, P. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-3166 · Cited by 117 · cited 1×
“Irrespective of how the disease progresses, it inevitably results in bilateral visual loss with profound emotional and psychological impact on the affected individuals and those around them [29].”
BackgroundNewman, N. J., Carelli, V., Taiel, M., & Yu-Wai-Man, P. (2020) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001045 · Cited by 111 · cited 2×
“[18] conducted a meta-analysis of 204 subjects with ND4 LHON aged ≥ 15 years at disease onset and revealed that only 11.”
BackgroundMethodSelf-citationBouquet, C., Vignal Clermont, C., Galy, A., Fitoussi, S., Blouin, L., Munk, M. R., Valero, S., Meunier, S., Katz, B., Sahel, J. A., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.6902 · Cited by 104 · cited 1×
“Importantly, no association was observed between intraocular inflammation and humoral or cellular immune response [41].”
BackgroundSelf-citationLam, B. L., Feuer, W. J., Schiffman, J. C., Porciatti, V., Vandenbroucke, R., Rosa, P. R., Gregori, G., & Guy, J. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.7971 · Cited by 96 · cited 2×
“A recent prospective natural history study of subjects with the 11778 ND4 mutation reported that 53% of patients showed bilateral involvement within 2 months after onset in the first eye, and 80% reported bilateral involvement within 6 months [25].”
BackgroundVisual BOLD Response in Late Blind Subjects with Argus II Retinal Prosthesis
Castaldi, E., Cicchini, G. M., Cinelli, L., Biagi, L., Rizzo, S., & Morrone, M. C. (2016) · PLoS Biology · doi:10.1371/journal.pbio.1002569 · Cited by 79 · cited 1×
“Finally, brain plasticity could account for an effect on visual function in the contralateral eye, as was shown for blind subjects implanted with retinal prosthesis [33].”
BackgroundChildhood-onset Leber hereditary optic neuropathy
Majander, A. S., Bowman, R. J. C., Poulton, J., Antcliff, R. J., Reddy, M. A., Michaelides, M., Webster, A. R., Chinnery, P. F., Votruba, M., Moore, A. T., et al. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-310072 · Cited by 79
Leber's Hereditary Optic Neuropathy-Gene Therapy: From Benchtop to Bedside
Koilkonda, R. D., & Guy, J. R. (2010) · Journal of Ophthalmology · doi:10.1155/2011/179412 · Cited by 72 · cited 1×
“On the other hand, the 11778-ND4 mutation is known to cause the most severe clinical form of LHON, with rare and poor visual spontaneous recovery in only approximately 4% of patients [2, 7, 8].”
BackgroundA MELAS-Associated ND1 Mutation Causing Leber Hereditary Optic Neuropathy and Spastic Dystonia
Spruijt, L., Smeets, H. J. M., Hendrickx, A. T. M., Bettink‐Remeijer, M. W., Maat‐Kievit, A., Schoonderwoerd, K. C., Sluiter, W. J., de Coo, I. F. M., & Hintzen, R. Q. (2007) · Archives of Neurology · doi:10.1001/archneur.64.6.890 · Cited by 62 · cited 1×
“LHON is a rare disease, with an estimated prevalence of between 1 in 30,000 and 1 in 50,000 reported in Northern Europe [4, 12, 13].”
BackgroundSeven-year follow-up of gene therapy for Leber’s hereditary optic neuropathy
Yuan, J., Zhang, Y., Liu, H., Wang, D., Du, Y., Tian, Z., Li, X., Yang, S., Pei, H., Wan, X., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.02.023 · Cited by 59
Retinal Ganglion Cell Dysfunction in Asymptomatic G11778A: Leber Hereditary Optic Neuropathy
Guy, J., Feuer, W. J., Porciatti, V., Schiffman, J., Abukhalil, F., Vandenbroucke, R., Rosa, P. R., & Lam, B. L. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13365 · Cited by 54 · cited 1×
“Subjects with ND4 LHON who are simply carriers of the 11778-ND4 mutation present a normal BCVA before the expression of the disease, and it has been shown that these non-affected patients with (asymptomatic) LHON (ND4 mutation carriers only) have a preserved BCVA (LogMAR 0; Snellen 20/20) [27, 28].”
BackgroundLiu, H., Yuan, J., Zhang, Y., Tian, Z., Li, X., Wang, D., Du, Y., Song, L., & Li, B. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14379 · Cited by 35
You, X. J., Gu, P., Wang, J., Song, T., Yang, J., Liew, C. G., & Klassen, H. J. (2010) · Journal of Ophthalmology · doi:10.1155/2011/378965 · Cited by 32
The Optic Neuritis Treatment Trial
Newman, N. J. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.046 · Cited by 25
Visual field variability after gene therapy for Leber’s hereditary optic neuropathy
Yuan, J.-J., Zhang, Y., Wang, L.-L., Cheng, M.-S., Ma, S.-Q., Gao, Q., & Li, B. (2018) · Ophthalmic Research · doi:10.1159/000487485 · Cited by 17
Cited by
Newman, N. J., Yu-Wai-Man, P., Biousse, V., & Carelli, V. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00174-0 · Cited by 97
Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy
Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A.-G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., et al. (2023) · Brain · doi:10.1093/brain/awac421 · Cited by 87
“The dose of lenadogene nolparvovec selected in REFLECT (9 × 10(10) vg/eye) was the maximal tolerated dose determined in the previous phase 1/2a REVEAL study.(15,21) This dose was also selected in the phase 3 studies RESCUE and REVERSE.”
Self-citationBiousse, V., Newman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Vignal-Clermont, C., Klopstock, T., Sadun, A. A., Sergott, R. C., Hage, R., et al. (2021) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001367 · Cited by 78
“Administered as a unilateral intravitreal injection to MT-ND4 patients, lenadogene nolparvovec showed a good safety profile in a phase 1/2 clinical trial including 5 years of followup after treatment administration (9).”
MethodSelf-citationNewman, N. J., Yu-Wai-Man, P., Carelli, V., Biousse, V., Moster, M. L., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Girmens, J.-F., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.662838 · Cited by 64
Self-citationDevelopments in the Treatment of Leber Hereditary Optic Neuropathy
Chen, B. S., Yu‐Wai‐Man, P., & Newman, N. J. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01246-y · Cited by 44
Metadata
- Authors
- Vignal-Clermont, C., Girmens, J.-F., Audo, I., Said, S. M., Errera, M.-H., Plaine, L., O’Shaughnessy, D., Taiel, M., & Sahel, J.-A.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- GenSight Biologics (France) (FR)
- Corresponding author
- Taiel, Magali
- Venue
- BioDrugs
- Published
- 2021-02-10
- Volume
- 35
- Issue
- 2
- Pages
- 201-214
- ISSN
- 1172-7039 (ISSN-L)
- 1173-8804
- 1179-190X
- PMC
- PMC7952288
- OpenAlex
- W3128161654
- Cited by
- 51
- References
- 42
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 4 · 2023: 9 · 2022: 13 · 2021: 4
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- BioDrugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- GenSight Biologics
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- Leber's hereditary optic neuropathy, intravitreal gene therapy, mitochondrial disease, visual acuity, safety and tolerability, ocular inflammation, dose escalation, idebenone, blindness prevention, long-term follow-up, ocular adverse effects
- MeSH terms
- Europe, Humans, Mutation, Visual Fields, Genetic Therapy, Optic Atrophy, Hereditary, Leber, Tomography, Optical Coherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.